胎儿先天性膈疝Smart气管封堵装置的无创移除:单臂开放标签1期研究
这项在法国巴黎和比利时鲁汶开展的两个平行单中心、单臂、开放标签1期研究,纳入48例患者(47例接受FETO,46例成功置入Smart-TO)。Smart-TO球囊在27+0至31+6周置入,计划在34+0至34+6周(或临床需要时更早)通过MRI磁场暴露诱导放气。主要终点放气率为100%(95%CI 92-100),出生时所有婴儿的空球囊均位于气道外。存活者中2例发生气管软化,出院时症状均缓解;14例新生儿死亡,均归因于肺发育不良。5例不良事件(共84例)被认为可能与装置相关,40例严重不良事件中无与Smart-TO装置相关者。
要点
- 在严重或中度肺发育不良的先天性膈疝胎儿中,Smart-TO球囊经MRI磁场诱导放气率为100%(95%CI 92-100)。
- 出生时所有婴儿的空球囊均位于气道外,无需第二次宫内操作来建立气道通畅。
- 存活者中2例发生气管软化,出院时症状均缓解;14例新生儿死亡均归因于肺发育不良。
- 84例不良事件中5例被认为可能与装置相关;40例严重不良事件中无与Smart-TO装置相关者。
- 作者认为该研究显示MRI诱导Smart-TO球囊放气有效并支持短期安全性,是先天性膈疝胎儿手术的重要进展。
适用人群与场景
- 年龄18岁及以上、单胎妊娠、左侧先天性膈疝伴严重或中度肺发育不良的患者;在鲁汶,还包括右侧和双侧先天性膈疝伴严重肺发育不良者。
- 胎儿肺大小通过超声测量观察值与预期肺头比评估。
- Smart-TO球囊置入计划在妊娠27+0周至31+6周之间进行。
诊断标准与关键阈值
- 胎儿肺大小通过超声测量观察值与预期肺头比评估。
- 球囊放气计划在妊娠34+0周至34+6周之间进行,或临床需要时更早。
处置流程与药物剂量
- 第一步:在妊娠27+0周至31+6周之间置入Smart-TO球囊。
- 第二步:在妊娠34+0周至34+6周之间(或临床需要时更早)将胎儿暴露于MRI机器磁场以诱导球囊放气。
- 第三步:放气后行超声检查确认球囊放气。
红旗征与不能漏的情况
- 置入后发生1例自发性球囊放气和1例不明原因宫内胎儿死亡。
- 存活者中发生2例气管软化,出院时症状均缓解。
- 发生14例新生儿死亡,均归因于肺发育不良。
研究设计与关键结果
- 研究类型:两个平行单中心、单臂、开放标签1期试验,在法国巴黎和比利时鲁汶开展。
- 样本量:2021年8月4日至2024年1月15日期间入组48例患者,其中47例接受FETO,46例胎儿成功置入Smart-TO。
- FETO时中位孕周为29+2周(28+5至30+1周)。
- 主要终点放气率为100%(95%CI 92-100)。
- 出生时所有婴儿的空球囊均位于气道外。
- 存活者中2例发生气管软化,出院时症状均缓解。
- 14例新生儿死亡,均归因于肺发育不良。
- 84例不良事件中5例被认为可能与装置相关;40例严重不良事件中无与Smart-TO装置相关者。
证据类型、等级与局限
- 证据类型:1期、首次人体、单臂、开放标签试验。
对床旁实践的改变
- 作者认为该研究显示MRI诱导Smart-TO球囊放气有效并支持短期安全性。
- 作者认为这些发现是先天性膈疝胎儿手术的重要进展,消除了第二次宫内操作的需要。
指南或共识出处
- ClinicalTrials.gov注册号NCT04931212(巴黎)和NCT05100693(鲁汶)。
- 资助:鲁汶大学医院临床研究与教育委员会(Klinische Onderzoeks-en Opleidingsraad)和巴黎公共援助医院;研究装置(Smart-TO)由BS-MTI免费提供给患者和机构。
提炼说明
- 本条依据论文摘要整理;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: One of the drawbacks of fetoscopic endoluminal tracheal occlusion (FETO) for congenital diaphragmatic hernia (CDH) is the need for a second intervention to establish airway patency. In this first-in-human study, we aimed to evaluate a novel tracheal occlusion device (Smart-TO) that spontaneously deflates when in close proximity to a strong magnetic field.
METHODS: We conducted two parallel single-centre, single-arm, open-label trials in Paris, France, and Leuven, Belgium. Eligibility criteria included patient age 18 years or more, singleton pregnancy with CDH, and severe or moderate pulmonary hypoplasia in left-sided CDH; in Leuven, eligibility criteria also included severe hypoplasia in right-sided and bilateral CDH. Fetal lung size was assessed by measuring the observed-to-expected lung-to-head ratio by ultrasonography. Data for baseline demographics were self-reported and collected at the screening visit. Insertion of the Smart-TO balloon was scheduled between 27+0 weeks and 31+6 weeks of gestation. Balloon deflation was scheduled between 34+0 weeks and 34+6 weeks (or earlier, if clinically indicated) by exposure to the magnetic field of a MRI machine, and ultrasonography was then done to confirm balloon deflation. The primary endpoint was balloon deflation, with expulsion of the balloon from the fetal airways at birth as a coprimary outcome in the Paris arm of the study. The primary outcome was reported with its 95% CI using the continuity-corrected score method for all patients with the investigational medical device in place at the time of deflation. Safety analysis was conducted for all patients in whom FETO was attempted. These trials are registered with ClinicalTrials.gov (NCT04931212 [Paris]) and NCT05100693 [Leuven]) and have been completed.
FINDINGS: Between Aug 4, 2021 and Jan 15, 2024, 48 patients were enrolled. Of these, 47 patients underwent FETO, and the Smart-TO was successfully placed in 46 fetuses. Median gestational age at FETO was 29+2 weeks (28+5-30+1 weeks). After placement, there was one spontaneous balloon deflation and one unexplained intrauterine fetal death. In all other patients, MRI machine-induced balloon deflation was attempted. The deflation rate was 100% (95% CI 92-100). At birth, the empty balloon was outside the airways in all infants. There were two cases of tracheomalacia in survivors, both with symptom resolution by the time of discharge from neonatal intensive care. There were 14 neonatal deaths, all attributed to pulmonary hypoplasia. Five adverse events were considered likely related to the device (of a total of 84), and no serious adverse events (of a total of 40) were related to the Smart-TO device.
INTERPRETATION: This study shows effective magnetic resonance-induced deflation of the Smart-TO balloon and supports short-term safety. These findings constitute an important advance in fetal surgery for CDH, eliminating the need for a second intrauterine procedure.
FUNDING: Clinical Council for Research and Education (Klinische Onderzoeks-en Opleidingsraad) of the University Hospitals of Leuven and Assistance Publique-Hôpitaux de Paris. Investigational devices (Smart-TO) were provided free of charge to patients and institutions by BS-MTI.
参考来源
- Russo FM, Sananès N, Letourneau A, et al. Non-invasive removal of the Smart tracheal occlusion device for fetal congenital diaphragmatic hernia: a single-arm, open-label, phase 1 study. Lancet. 2026. PMID: 42335922. doi:10.1016/S0140-6736(26)00664-1
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。